How would you define the success of Baxter International's Floseal Hemostatic Matrix?

Introduction

Defining the success of Baxter International's Floseal Hemostatic Matrix requires a comprehensive approach that considers multiple stakeholders and metrics. To address this product success metrics challenge effectively, I'll follow a structured framework covering core metrics, supporting indicators, and risk factors while considering all key stakeholders.

Step 1

Product Context

Floseal Hemostatic Matrix is a surgical hemostatic agent developed by Baxter International. It's designed to stop bleeding during complex surgical procedures, particularly in cardiovascular, spine, and orthopedic surgeries. The product consists of a granular gelatin matrix and a human thrombin component, which are mixed and applied to the bleeding site.

Key stakeholders include:

• Surgeons: Seeking effective, easy-to-use hemostatic solutions
• Patients: Requiring safe and effective surgical outcomes
• Hospitals: Looking for cost-effective products that improve patient care
• Regulatory bodies: Ensuring product safety and efficacy
• Baxter International: Aiming to grow market share and revenue

User flow:

1. Preparation: Surgical team prepares Floseal by mixing components
2. Application: Surgeon applies Floseal to the bleeding site
3. Activation: Floseal interacts with patient's blood to form a clot
4. Monitoring: Surgical team observes hemostasis and reapplies if necessary

Floseal fits into Baxter's broader strategy of providing innovative solutions for complex medical challenges, particularly in surgical care. It competes with other hemostatic agents like Surgiflo and Surgicel, differentiating itself through its rapid action and effectiveness in high-flow bleeding situations.

Product Lifecycle Stage: Floseal is in the maturity stage, having been on the market for over a decade. It's well-established but faces increasing competition and pressure to innovate.

Physical Product Considerations:

• Distribution channels: Primarily through hospital supply chains and direct sales to surgical centers
• Shelf-life: Typically 18-24 months, requiring careful inventory management
• Sales model: Combination of direct sales force and distributor networks